[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 4 sources · 7 days · First seen · Last updated

Sotagliflozin cardiovascular research

Overview

Researchers at Michigan Medicine have identified a mechanism explaining how the diabetes medication sotagliflozin, marketed as Inpefa, reduces the risk of heart attack and stroke. Laboratory experiments published in the Journal of Clinical Investigation indicate that the drug prevents excessive platelet activation, which typically triggers blood clots in the heart and brain.

Unlike other SGLT2 inhibitors such as empagliflozin or dapagliflozin that primarily act on the kidneys, sotagliflozin targets both SGLT2 and SGLT1 proteins. In comparative tests, sotagliflozin limited platelet aggregation in human samples, while other inhibitors showed little to no effect. In animal models with damaged blood vessels, the treatment reduced clot formation by approximately 60 percent.

Entities

sotagliflozin · University of Michigan · India · Michael A. Holinstat · Journal of Clinical Investigation

Timeline

  1. [HEALTH] 2 sources
    Diabetes research highlights new drug benefits for blood clots and glycemic control

    Researchers have identified potential blood-clot prevention benefits of the diabetes drug sotagliflozin, while a new phase III trial shows a three-drug combination improves glycemic control in Indian patients.

  2. [HEALTH] 2 sources
    Michigan Medicine researchers identify mechanism for diabetes drug's cardiovascular benefits

    Michigan Medicine researchers discovered that the diabetes drug sotagliflozin reduces heart attack and stroke risks by preventing excessive platelet activation and blood clot formation.

Sources

consalud.es · knowridge.com · news-medical.net · newswise.com